<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742208</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-203-T1DM</org_study_id>
    <secondary_id>LX4211.203</secondary_id>
    <nct_id>NCT01742208</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This Phase 2 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),
      safety and efficacy of LX4211 following daily oral administration for 29 days in patients
      with type 1 diabetes mellitus (T1DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of LX4211 on the total daily bolus amount of exogenous insulin required to maintain or improve glycemic control</measure>
    <time_frame>Daily, Baseline through Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess total exogenous daily bolus and basal insulin use</measure>
    <time_frame>Daily, Baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the amount of exogenous use at each meal</measure>
    <time_frame>Daily, Baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Days -1, 1-3, 8, 13, 28-31 and 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels as measured by Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Week 1 through week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose by Area Under Curve (AUC)</measure>
    <time_frame>Day 1 and Day 29; predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LX4211 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioneer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>Subjects will receive LX4211 once daily for 29 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 Placebo</intervention_name>
    <description>Subjects will receive LX4211 placebo once daily for 29 days</description>
    <arm_group_label>LX4211 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>Subjects will receive LX4211 once daily for 29 days; pioneer subjects will complete dosing prior to dosing any other study subjects.</description>
    <arm_group_label>Pioneer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 to ≤55 years of age

          -  Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6
             months prior to Screening

          -  Willing to refrain from using carbohydrate counting to adjust insulin during the study

          -  Willing and able to wear and operate a continuous glucose monitor

          -  Willing and able to self-assess blood-glucose

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's
             disease, chronic pancreatitis, or pancreatectomy

          -  Two or more severe episodes of hypoglycemia that required emergency treatment within 3
             months prior to Screening

          -  Use of premixed insulin

          -  History of diabetic ketoacidosis within 1 year of screening

          -  Presence of active hepatic disease or clinically significant abnormal liver function
             tests

          -  History of chronic pancreatitis

          -  Subjects with a history of heart attack, severe/unstable angina, or coronary
             revascularization procedure

          -  History of clinically significant cardiac arrhythmias within 1 year prior to screening

          -  Subjects with congestive heart failure

          -  Subjects with uncontrolled Stage III hypertension

          -  History of human immunodeficiency virus (HIV) or hepatitis C

          -  History of illicit drug or alcohol abuse within 12 months prior to Screening

          -  Use of any investigational agent or device within 30 days prior to Screening or any
             therapeutic protein or antibody within 90 days prior to Screening

          -  Use of medication or herbal supplements taken for weight loss within 2 weeks of
             screening

          -  Chronic use of any antidiabetic therapy other than insulin within 2 months prior to
             Screening

          -  Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening

          -  Subjects who have undergone major surgery within 6 months prior to Screening

          -  Inability or difficulty swallowing whole tablets or capsules

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Strumph, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <disposition_first_submitted>January 14, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2015</disposition_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

